Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0278 • ACR Convergence 2021
Higher Prevalence of Eccentric Hypertrophy in Rheumatoid Arthritis Patients: A Case-Control Study
Alejandra Rodriguez-Romero, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Natalia Guajardo-Jauregui, Julieta Loya-Acosta, Alejandro Meza-Garza, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Alan De Leon-Yañez and Catalina Andrade-Vazquez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of cardiovascular diseases and a strong association with abnormalities in the left ventricular (LV) geometry.…
Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Misako Higashida-Konishi¹, Keisuke Izumi², Tatsuya Shimada³, Satoshi Hama⁴, Mitsuhiro Akiyama⁵, Hisaji Oshima⁴ and Yutaka Okano⁶, ¹Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ⁵Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Palo Alto, CA, ⁶Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…
Abstract Number: 0515 • ACR Convergence 2021
The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel, Sang Han and Salah-uddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Recent unpublished findings from our lab show that the extracellular enzyme sulfatase-2 (Sulf-2) facilitates pro-inflammatory TNF-α signaling which activates rheumatoid arthritis synovial fibroblasts (RASFs).…
Abstract Number: 0579 • ACR Convergence 2021
Predicting Treatment Change in Rheumatoid Arthritis Patients Treated with TNF Inhibitors as First-Line Biologic Agent
Yinzhu Jin¹, Joan Landon¹, Whitney Krueger², Alexander Liede² and Seoyoung Kim³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²AbbVie Global Epidemiology, Chicago, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patient characteristics including serostatus, body mass index (BMI), and smoking are considered to be associated with their response to disease-modifying anti-rheumatic drugs (DMARD) treatment…
Abstract Number: 0608 • ACR Convergence 2021
Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients
Valerie Umaefulam¹, Terri-Lynn Fox¹, Glen Hazlewood¹, Nick Bansback², Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patient decision aids (PtDA) can enable shared decision-making between patients and healthcare providers. We have previously developed a PtDA for first-line methotrexate-based treatment options…
Abstract Number: 0787 • ACR Convergence 2021
Association of Hemoglobin Levels and Radiographic Progression in the BRASS Registry
Nancy Shadick¹, Owen Hagino², Amy Praestgaard³, Stefano Fiore², Michael Weinblatt⁴ and Gerd Burmester⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Sanofi, Bridgewater, NJ, ³Sanofi, Cambridge, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: To evaluate baseline hemoglobin (Hb) and radiographic progression over time for patients in the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS) registry.Methods:…
Abstract Number: 0803 • ACR Convergence 2021
Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists
William Arnold¹, Erin Arnold¹, David Sikes², Gary Crump³, Kathleen Thomas⁴ and andrew johnson⁵, ¹Arnold Arthritis and Rheumatology, Wilmette, IL, ²Florida Medical Clinic, Wesley Chapel, FL, ³Rheumatology Associates, Louisville, KY, ⁴Community Health Network, Noblesville, IN, ⁵PopMed Solutions, Boyds, MD
Background/Purpose: The RAPP quality improvement project is a voluntary consortium of practicing rheumatologists founded in 2013 by Timothy Harrington MD, MACR. The primary focus is…
Abstract Number: 0821 • ACR Convergence 2021
Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study
Rieke Alten¹, Xavier Mariette², Mauro Galeazzi³, Melanie Chartier⁴, Christiane Rauch⁵, Yedid Elbez⁶ and Karissa Lozenski⁷, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³University of Siena, Siena, Italy, ⁴Bristol Myers Squibb, Rueil-Malmaison, France, ⁵Bristol Myers Squibb, Munich, Germany, ⁶Deepscover, Puteaux, France, ⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Identifying factors associated with treatment response and remission in patients with RA may assist with therapeutic decision-making. An international observational study evaluated efficacy and…
Abstract Number: 0838 • ACR Convergence 2021
Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans
Tawnie Braaten¹, shaobo Pei², Anitha Rathod², Gopi Penmetsa³, Kevin Douglas⁴, Jodi Walker⁴, Jerry Clewell⁵ and Jessica Walsh⁶, ¹Salt Lake City Veteran Affairs and University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., North Chicago, IL, ⁵Abbvie Inc, North Chicago, IL, ⁶Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Non-treatment and treatment delays contribute to suboptimal symptom control and irreversible joint damage in patients with inflammatory arthritis (IA). This investigations objective was to…
Abstract Number: 0982 • ACR Convergence 2021
B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach
Aurelie Najm¹, Shrutii Sarda², Michelle Toro³, Loni Pickle³, Stephanie Ostresh³, Fraser Morton⁴, Geoffrey Lowman³, Andrew Felton⁵ and Carl Goodyear⁴, ¹Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Clinical Sequencing Division, Specialty Diagnostics Group, Thermo Fisher Scientific, South San Francisco-CA, United States, San Francisco, ³Clinical Sequencing Division, Specialty Diagnostics Group, Thermo Fisher Scientific, Carlsbad, CA, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵VP, Platforms, Research & Applied, Specialty Diagnostics Group, South San Francisco, CA
Background/Purpose: The adaptive immune system plays a central role in Rheumatoid Arthritis (RA) pathogenesis. Moreover, the composition of the B cell repertoire and its perturbation…
Abstract Number: 1067 • ACR Convergence 2021
Experiences of Self-Care During the COVID-19 Pandemic Among Individuals with Rheumatoid Arthritis: A Qualitative Study
Jenny Leese¹, Catherine L. Backman¹, Jasmin Ma¹, Cheryl Koehn², Alison Hoens³, Kelly English³, Eileen Davidson⁴, Shanon McQuitty³, James Gavin⁵, Jo Adams⁵, Stephanie Thierren⁶ and Linda Li¹, ¹University of British Columbia, Vancouver, BC, Canada, ²Arthritis Consumer Experts, Vancouver, BC, Canada, ³Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ⁴Arthritis Research Canada Arthritis Patient Advisory Board, Burnaby, BC, Canada, ⁵University of Southampton, Southampton, United Kingdom, ⁶Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: The COVID-19 pandemic poses new challenges for individuals with rheumatoid arthritis (RA) to manage their self-care, such as being physically active, maintaining emotional wellbeing,…
Abstract Number: 1198 • ACR Convergence 2021
Ultrasonography of the Median Nerve in Patients with Rheumatoid Arthritis Under Suspicion of Carpal Tunnel Syndrome
Styliani Tsiami¹, Efthymia Ntasiou², Christos Krogias², Ralf Gold², Jürgen Braun¹, Michael Sarholz³ and Xenofon Baraliakos¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Josef-Hospital, Bochum and Ruhr-University Bochum, Germany, Bochum, Germany, ³Klinik fuer Rheumatologie, St. Marien-Hospital Vreden, Vreden, Germany
Background/Purpose: Carpal tunnel syndrome (CTS) is the most common nerve compression syndrome and a common extra-articular manifestation of rheumatoid arthritis (RA). Different causes of CTS…
Abstract Number: 1214 • ACR Convergence 2021
Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
Kristin Wipfler¹, Joshua Baker², Harlan Sayles³, Xue Han⁴, Sang Hee Park⁴, Keith Wittstock⁴, Ted Mikuls³ and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The shared epitope (SE) is an amino acid sequence motif coded by several HLA-DRB1 alleles that are overrepresented among people with rheumatoid arthritis (RA).…
Abstract Number: 1230 • ACR Convergence 2021
Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Jeffrey Sparks², Arnaud Constantin³, Ricardo Xavier⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Toulouse University Hospital, Toulouse Cedex 9, France, ⁴Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵AbbVie Inc., North Chicago, IL, ⁶University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority…
Abstract Number: 1246 • ACR Convergence 2021
The Effect of Tocilizumab on miR-146a-5p and EMMPRIN/CD147 in Rheumatoid Arthritis Patients
Devy Zisman¹, Mirna Safieh¹, Elina Simanovich¹, Joy Feld², Amalia Kinarty¹, Liron Zisman¹, Tal Gazitt³, Amir Haddad⁴, Muna Elias¹, Itzhak Rosner⁵, Lisa Kaly⁶ and Michal A Rahat⁷, ¹Carmel Medical Center, Haifa, Israel, ²Carmel and Zvulun Medical Centre, Haifa, Israel, ³Carmel Hospital, Haifa, Israel, ⁴Carmel Medical Centre, Haifa, Israel, ⁵Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ⁶Bnei Zion Medical Center, Haifa, Israel, ⁷Carmel Medical Center/Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Background/Purpose: Angiogenesis is an important contributor to the development of rheumatoid arthritis (RA). Tocilizumab (TCZ), an anti-IL-6 receptor antibody used in the treatment of RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].